Department of Ophthalmology, Veroia General Hospital, Veroia, Greece.
Ophthalmology. 2011 Apr;118(4):730-5. doi: 10.1016/j.ophtha.2010.08.039. Epub 2010 Dec 18.
To evaluate risk factors (hypertension, diabetes mellitus, and current tamsulosin, alfuzosin, terazosin, or doxazosin use) for intraoperative floppy iris syndrome (IFIS) in patients undergoing phacoemulsification cataract surgery.
Systematic review and meta-analysis of the literature.
Seventeen eligible studies (17 588 eyes) examining the association between IFIS and risk factors.
Pertinent publications were identified through a systematic search of PubMed. All references of relevant reviews and eligible articles were also screened. Language restrictions were not used, and data were extracted from each eligible study by 2 investigators working independently. For medications, 2 separate analyses were performed: an analysis using a dichotomous criterion (use/non-use of the examined agent) and an alternative analysis performing comparisons with patients not receiving any α(1)-blocker. The fixed-effects model (Mantel-Haenszel method) or the random-effects (DerSimonian Laird) model was appropriately used to calculate the pooled odds ratio (OR). Publication bias was appropriately assessed.
Pooled OR for the incidence of IFIS.
The pooled OR for IFIS after tamsulosin use was approximately 40-fold greater (or 16.5 at the alternative analysis) than that after alfuzosin use, that is, the second α(1)-blocker in order of effect size. Alfuzosin and terazosin were also associated with IFIS with comparable ORs; the effect of doxazosin reached formal statistical significance at the alternative analysis. Intraoperative floppy iris syndrome was positively associated with hypertension (pooled OR = 2.2, 95% confidence interval [CI], 1.2-4.2, fixed effects) but not with diabetes mellitus (pooled OR = 1.3, 95% CI, 0.7-2.2, fixed effects).
This meta-analysis has highlighted a hierarchy concerning the role of α(1)-blockers in IFIS, indicating an extremely sizeable effect size of tamsulosin; this may entail important physiologic implications. Alfuzosin, terazosin, and doxazosin presented with comparable effect sizes. Hypertension, but not diabetes mellitus, emerged as a risk factor for IFIS.
评估行白内障超声乳化术患者术中眼虹膜松弛综合征(IFIS)的危险因素(高血压、糖尿病、以及当前坦索罗辛、阿呋唑嗪、特拉唑嗪或多沙唑嗪的使用)。
文献的系统回顾和荟萃分析。
17 项研究(17588 只眼)符合 IFIS 与危险因素相关性的研究。
通过对 PubMed 的系统检索,确定相关文献。还对相关综述和合格文章的所有参考文献进行了筛选。未使用语言限制,由 2 位独立研究人员从每项合格研究中提取数据。对于药物,进行了 2 项独立分析:一项使用二分类标准(使用/未使用所检查药物)的分析,以及一项与未使用任何 α1-受体阻滞剂患者进行比较的替代分析。使用固定效应模型(Mantel-Haenszel 方法)或随机效应(DerSimonian Laird)模型适当计算合并比值比(OR)。适当评估发表偏倚。
IFIS 的发生率的合并 OR。
坦索罗辛使用后 IFIS 的合并 OR 大约为阿呋唑嗪使用后的 40 倍(或替代分析中的 16.5),即按作用大小排序的第二种 α1-受体阻滞剂。阿呋唑嗪和特拉唑嗪与 IFIS 也有相关性,其 OR 相当;多沙唑嗪的作用在替代分析中达到了统计学显著性。IFIS 与高血压呈正相关(合并 OR = 2.2,95%置信区间 [CI],1.2-4.2,固定效应),但与糖尿病无相关性(合并 OR = 1.3,95% CI,0.7-2.2,固定效应)。
本荟萃分析强调了 α1-受体阻滞剂在 IFIS 中的作用等级,表明坦索罗辛的作用强度极大;这可能涉及重要的生理意义。阿呋唑嗪、特拉唑嗪和多沙唑嗪具有相当的作用强度。高血压,而不是糖尿病,是 IFIS 的危险因素。